Citations

Mayo Clinic

Showing 10 of 108523 citations.

Book Reviews
Tangalos, Eric G.

Journal of the American Geriatrics Society | April 29, 2015 | Volume: 40 | Issue: 8 | Pages: 857-857

10.1111/j.1532-5415.1992.tb01868.x Get It

Principles and Practice of Nursing Home Care . Edited by Paul R. Katz, MD and Evan Calkins, MD. New York, Springer Publishing Company, Inc., 1989. 443 pages. $43.95.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
Witzig, Thomas E. , Reeder, Craig B. , LaPlant, Betsy, Stenson, Mary, Macon, William R. , Ansell, Stephen M. , Inwards, David J. , Micallef, Ivana N. , Johnston, Patrick B. , Porrata, Luis F. , Nowakowski, Grzegorz S. , Reeder, Craig, Han, Jing-Jing, Tun, Han W. , Macon, William, Colgan, Joseph P. , Witzig, T.E. , Han, Jing , Habermann, Thomas M. , Markovic, Svetomir N. , Gupta, Mamta

Blood | April 28, 2015 | Volume: 126 | Issue: 3 | Pages: 328-335

10.1182/blood-2015-02-629543 | PMID 25921059 Get It

Key Points The mTOR pathway is constitutively activated in the TCL cells and is responsible for TCL proliferation. This is first trial to demonstrate that mTORC1 inhibitors (everolimus) have substantial antitumor activity (44% overall response rate) in patients with relapsed TCL.
Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue
Sagar, Gunisha, Sah, Raghuwansh P., Javeed, Naureen , Dutta, Shamit K., Smyrk, Thomas C. , Lau, Julie S., Giorgadze, Nino, Tchkonia, Tamar , Kirkland, James L. , Chari, Suresh T. , Mukhopadhyay, Debabrata , Tchkonia, T , Chari, Suresh T

Gut | April 28, 2015 | Volume: 65 | Issue: 7 | Pages: 1165-1174

10.1136/gutjnl-2014-308350 | PMID 26061593 Get It

Background and objectives New-onset diabetes and concomitant weight loss occurring several months before the clinical presentation of pancreatic cancer (PC) appear to be paraneoplastic phenomena caused by tumour-secreted products. Our recent findings have shown exosomal adrenomedullin (AM) is important in development of diabetes in PC. Adipose tissue lipolysis might explain early onset weight loss in PC. We hypothesise that lipolysis-inducing cargo is carried in exosomes shed by PC and is responsible for the paraneoplastic effects. Therefore, in this study we investigate if exosomes secreted by PC induce lipolysis in adipocytes and explore the role of AM in PC-exosomes as the mediator of this lipolysis. Design Exosomes from patient-derived cell lines and from plasma of patients with PC and non-PC controls were isolated and characterised. Differentiated murine (3T3-L1) and human adipocytes were exposed to these exosomes to study lipolysis. Glycerol assay and western blotting were used to study lipolysis. Duolink Assay was used to study AM and adrenomedullin receptor (ADMR) interaction in adipocytes treated with exosomes. Results In murine and human adipocytes, we found that both AM and PC-exosomes promoted lipolysis, which was abrogated by ADMR blockade. AM interacted with its receptor on the adipocytes, activated p38 and extracellular signal-regulated (ERK1/2) mitogen-activated protein kinases and promoted lipolysis by phosphorylating hormone-sensitive lipase. PKH67-labelled PC-exosomes were readily internalised into adipocytes and involved both caveolin and macropinocytosis as possible mechanisms for endocytosis. Conclusions PC-secreted exosomes induce lipolysis in subcutaneous adipose tissue; exosomal AM is a candidate mediator of this effect.
Detection of IGF-1 Protein Variants by Use of LC-MS with High-Resolution Accurate Mass in Routine Clinical Analysis
Hines, Jolaine, Ketha, Hemamalini , Grebe, Stefan K., Milošević, Dragana , Taylor, Robert L. , Algeciras‐Schimnich, Alicia , Singh, Ravinder

Clinical Chemistry | April 28, 2015 | Volume: 61 | Issue: 7 | Pages: 990-991

10.1373/clinchem.2014.234799 | PMID 25922441 Get It

Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary
Weinshenker, Brian G. , Weinshenker, Brian G

Multiple Sclerosis Journal | April 28, 2015 | Volume: 21 | Issue: 6 | Pages: 693-694

10.1177/1352458515580402 | PMID 25921043 Get It

Is mastectomy undertreatment for low‐risk breast cancers eligible for breast‐conserving therapy?
Wasif, Nabil , Rawal, Bhupendra, McLaughlin, Sarah A., Giuliano, Armando E. , Bagaria, Sanjay P.

Cancer | April 28, 2015 | Volume: 121 | Issue: 16 | Pages: 2705-2712

10.1002/cncr.29416 | PMID 25920382 Get It

BACKGROUNDBiomarkers are routinely used to predict responses to systemic therapies, but their utility for predicting responses to local therapy for breast cancer is not known. This study determined whether biomarkers could predict responses to breast‐conserving therapy (BCT) and mastectomy.METHODSA review of the Surveillance, Epidemiology, and End Results database identified women diagnosed with early‐stage invasive ductal breast cancer and treated with BCT or mastectomy from 1998 to 2008. The estrogen receptor (ER) status and the histologic grade were used to construct 3 biomarker profiles: low risk (ER‐positive, low/intermediate grade), intermediate risk (ER‐positive, high grade), and high risk (ER‐negative, any grade). The primary measured outcome was disease‐specific survival (DSS).RESULTSBCT and mastectomy were performed in 114,486 patients (59.2%) and 79,035 patients (40.8%), respectively. There were 122,420 low‐risk patients (63.3%), 34,341 intermediate‐risk patients (17.7%), and 36,760 high‐risk patients (19.0%). Multivariate analyses were performed separately for patients with low‐, intermediate‐, and high‐risk tumors. The adjusted hazard ratios for DSS for patients who underwent mastectomy versus BCT for low‐, intermediate‐, and high‐risk tumors were 1.66 (95% confidence interval [CI], 1.54‐1.79; P < .001), 1.40 (95% CI, 1.29‐1.53; P < .001), and 1.27 (95% CI, 1.19‐1.35; P < .001), respectively.CONCLUSIONSPatients with ER‐positive, low‐grade breast cancers who underwent mastectomy had a 66% increase in disease‐specific mortality versus those who underwent BCT. Biomarker profiles defined by the ER status and grade may improve the selection of local therapy for breast cancer. Cancer 2015;121:2705‐2712. © 2015 American Cancer Society
Commentary
Lieske, John C.

Clinical Chemistry | April 28, 2015 | Volume: 61 | Issue: 5 | Pages: 702-703

10.1373/clinchem.2014.231803 Get It

Robust Neuritogenesis‐Promoting Activity by Bis(heptyl)‐Cognitin Through the Activation of alpha7‐Nicotinic Acetylcholine Receptor/ERK Pathway
Hu, Shengquan, Cui, Wei , Mak, Shinghung , Choi, Chung‐Lit, Y, Hu , Li, Gang , Tsim, Karl Wah Keung , Pang, Yuan‐Ping , Han, Yifan , Han, Yifan , Pang, Yuan-Ping

CNS Neuroscience & Therapeutics | April 28, 2015 | Volume: 21 | Issue: 6 | Pages: 520-529

10.1111/cns.12401 | PMID 25917415 Get It

SummaryAimsNeurodegenerative disorders are caused by progressive neuronal loss in the brain, and hence, compounds that could promote neuritogenesis may have therapeutic values. In this study, the effects of bis(heptyl)‐cognitin (B7C), a multifunctional dimer, on neurite outgrowth were investigated in both PC12 cells and primary cortical neurons.MethodsImmunocytochemical staining was used to evaluate the proneuritogenesis effects, and Western blot and short hairpin RNA assays were applied to explore the underlying mechanisms.ResultsB7C (0.1–0.5 μM) induced robust neurite outgrowth in PC12 cells, as evidenced by the neurite‐bearing morphology and upregulation of growth‐associated protein‐43 expression. In addition, B7C markedly promoted neurite outgrowth in primary cortical neurons as shown by the increase in the length of β‐III‐tubulin‐positive neurites. Furthermore, B7C rapidly increased ERK phosphorylation. Specific inhibitors of alpha7‐nicotinic acetylcholine receptor (α7‐nAChR) and MEK, but not those of p38 or JNK, blocked the neurite outgrowth as well as ERK phosphorylation induced by B7C. Most importantly, genetic depletion of α7‐nAChR significantly abolished B7C‐induced neurite outgrowth in PC12 cells.ConclusionB7C promoted neurite outgrowth through the activation of α7‐nAChR/ERK pathway, which offers novel insight into the potential application of B7C in the treatment of neurodegenerative disorders.
Palliative Oncologists: Specialists in the Science and Art of Patient Care
Finlay, Esmé , Buss, Mary K. , Prommer, Eric , Hui, David, Prommer, Eric E, Bruera, Eduardo, Hui, David , Bruera, Eduardo

Journal of Clinical Oncology | April 28, 2015 | Volume: 33 | Issue: 20 | Pages: 2314-2317

10.1200/jco.2014.60.3274 | PMID 25918292 Get It

Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell Wall
Hebrink, Deanne, Jenson, Paige E., Kottom, Theodore J. , Hebrink, Deanne M, Guðmundsson, Gunnar , Limper, Andrew H.

Infection and Immunity | April 28, 2015 | Volume: 83 | Issue: 7 | Pages: 2816-2826

10.1128/iai.00196-15 | PMID 25916991 Get It

ABSTRACT Inflammation is a major cause of respiratory impairment during Pneumocystis pneumonia. Studies support a significant role for cell wall β-glucans in stimulating inflammatory responses. Fungal β-glucans are comprised of d -glucose homopolymers containing β-1,3-linked glucose backbones with β-1,6-linked glucose side chains. Prior studies in Pneumocystis carinii have characterized β-1,3 glucan components of the organism. However, recent investigations in other organisms support important roles for β-1,6 glucans, predominantly in mediating host cellular activation. Accordingly, we sought to characterize β-1,6 glucans in the cell wall of Pneumocystis and to establish their activity in lung cell inflammation. Immune staining revealed specific β-1,6 localization in P. carinii cyst walls. Homology-based cloning facilitated characterization of a functional P. carinii kre6 ( Pckre6 ) β-1,6 glucan synthase in Pneumocystis that, when expressed in kre6 -deficient Saccharomyces cerevisiae , restored cell wall stability. Recently synthesized β-1,6 glucan synthase inhibitors decreased the ability of isolated P. carinii preparations to generate β-1,6 carbohydrate. In addition, isolated β-1,6 glucan fractions from Pneumocystis elicited vigorous tumor necrosis factor alpha (TNF-α) responses from macrophages. These inflammatory responses were significantly dampened by inhibition of host cell plasma membrane microdomain function. Together, these studies indicate that β-1,6 glucans are present in the P. carinii cell wall and contribute to lung cell inflammatory activation during infection.